Securities and Exchange Commission (Nigeria)

LiveOne Reports Q2 Fiscal Year 2024 Revenue of $28.5M and Adjusted EBITDA* of $2.8M

Retrieved on: 
Thursday, November 9, 2023
Net operating loss, Event, EBITDA, Average cost, Securities and Exchange Commission (Nigeria), Software, Webcast, Capital expenditure, Car rental, LiveOne

PodcastOne revenue was $10.5 million, a 24% increase compared to revenue of $8.5 million in Q2 Fiscal 2023.

Key Points: 
  • PodcastOne revenue was $10.5 million, a 24% increase compared to revenue of $8.5 million in Q2 Fiscal 2023.
  • Q2 Fiscal 2024 Operating Loss was ($2.5) million compared to Operating Loss of ($1.0) million in Q2 Fiscal 2023.
  • Q2 Fiscal 2024 Adjusted EBITDA* of $2.8 million decreased as compared to Q2 Fiscal 2023 Adjusted EBITDA* of $4.4 million, which was primarily driven by settlements in the prior period.
  • Q2 Fiscal 2024 Adjusted EBITDA* was comprised of Slacker Adjusted EBITDA* of $5.0 million and PodcastOne Adjusted EBITDA* of $0.1 million.

DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Reverse Split of Outstanding and Issued Common Stock and Conversion of Certain Holder’s Common Stock

Retrieved on: 
Wednesday, November 8, 2023
Security (finance), NYSE, DSS, Securities and Exchange Commission (Nigeria), DBH, Impact

Impact did not effectuate a reverse split of its authorized capital stock and no amendment to the articles of incorporation or bylaws was made.

Key Points: 
  • Impact did not effectuate a reverse split of its authorized capital stock and no amendment to the articles of incorporation or bylaws was made.
  • Impact received approval from its majority stockholder and the Company’s Board of Directors to effectuate the reverse split.
  • In addition to the reverse split, Impact’s Form 8-K discloses DSS BioHealth Security, Inc.’s, (“DBH”) conversion of substantially all of its 87.5% common stock equity interest in Impact into an equivalent number of Series A Convertible Preferred Stock.
  • The Series A Convertible Preferred Stock can be converted back to Impact Biomedical common stock 75 days after October 31, 2023.

Star Equity Holdings, Inc. Announces 2023 Third Quarter Financial Results

Retrieved on: 
Wednesday, November 8, 2023
Sale, Loss, Security (finance), Event, Health care, EBITDA, Conference, Securities and Exchange Commission (Nigeria), Exhibit, Investment, Webcast, Depreciation, Conference call, Reinsurance

On a consolidated basis, Q3 2023 sales, general and administrative (“SG&A”) expenses increased by $0.3 million, or 10.9%, versus the prior year period.

Key Points: 
  • On a consolidated basis, Q3 2023 sales, general and administrative (“SG&A”) expenses increased by $0.3 million, or 10.9%, versus the prior year period.
  • SG&A as a percentage of revenue increased in Q3 2023 to 32.9% versus 27.9% in Q3 2022.
  • The record date for this dividend was September 1, 2023, and the payment date was September 12, 2023.
  • Use of Non-GAAP Financial Measures by Star Equity Holdings, Inc.

NYSE to Commence Delisting Proceedings Against Heliogen, Inc. (HLGN)

Retrieved on: 
Tuesday, November 7, 2023
Professional Services, Finance, Committee, Security (finance), Securities and Exchange Commission (Nigeria), Exchange, NYSE

NYSE Regulation reached its decision to delist the Company’s Securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000.

Key Points: 
  • NYSE Regulation reached its decision to delist the Company’s Securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000.
  • The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange.
  • The NYSE will apply to the Securities and Exchange Commission to delist the Securities upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20231107769573/en/

IDACORP, Inc. Announces Public Offering of $260 Million of Shares of Common Stock

Retrieved on: 
Tuesday, November 7, 2023
Professional Services, Utilities, Alternative Energy, Energy, Finance, Construction & Property, REIT, Varick Street, Sale, Security (finance), NYSE, Morgan Stanley, Idacorp, Public expenditure, Telephone, IDA, Securities and Exchange Commission (Nigeria), Attention, Hudson Yards, Prospectus, 2nd Floor, Wells Fargo, IDACORP

IDACORP, Inc. (NYSE: IDA) announced today that it has commenced an underwritten public offering of $260 million of shares of its common stock.

Key Points: 
  • IDACORP, Inc. (NYSE: IDA) announced today that it has commenced an underwritten public offering of $260 million of shares of its common stock.
  • In conjunction with the offering, IDACORP intends to grant to the underwriters an option to purchase up to $39 million of additional shares of its common stock.
  • Settlement of the forward sale agreement is expected to occur no later than 12 months following the completion of the offering.
  • IDACORP will not initially receive any proceeds from the sale of shares of its common stock by the forward counterparty (or affiliates thereof) to the underwriters.

Perella Weinberg Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 7, 2023
Insurance, Treasury, International, PWP, GAAP, Securities and Exchange Commission (Nigeria), Common stock, Perella Weinberg Partners, Partnership, Webcast, Travel, Settlement, Domestic, United States Department of the Treasury, Investment, Holt, Security (finance)

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Perella Weinberg Partners (the “Firm” or “PWP”) (NASDAQ:PWP) today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • GAAP total compensation and benefits were $127.8 million for the third quarter of 2023, compared to $123.3 million for the third quarter of 2022.
  • GAAP non-compensation expenses were $37.9 million for the third quarter of 2023, compared with $30.9 million for the third quarter of 2022.
  • Adjusted non-compensation expenses were $34.3 million for the third quarter of 2023, compared with $27.8 million for the same period a year ago.
  • Management will host a webcast and conference call on Tuesday, November 7, 2023 at 9:00 am ET to discuss PWP’s financial results for the third quarter ended September 30, 2023.

Plus Therapeutics Announces Share Repurchase Program

Retrieved on: 
Tuesday, October 31, 2023
Security (finance), Share repurchase, Plus Therapeutics, Securities and Exchange Commission (Nigeria), Therapy, PSTV, Pharmaceutical industry

AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that its Board of Directors has approved a share repurchase program, with authorization to repurchase up to $500,000 of the Company’s outstanding common stock.

Key Points: 
  • AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that its Board of Directors has approved a share repurchase program, with authorization to repurchase up to $500,000 of the Company’s outstanding common stock.
  • The Company intends to fund any share repurchases with available cash.
  • “We are committed to delivering long-term value to shareholders, and this repurchase program reinforces our confidence in our future and our ability to execute on strategic priorities,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • The Company is not obligated to acquire any shares and the program may be discontinued or suspended at any time.

IBC Continues to Deliver Exceptional Earnings

Retrieved on: 
Thursday, November 2, 2023
Banking, Professional Services, Finance, Insurance, FDIC, Security (finance), International Bancshares Corporation, IBOC, Federal Reserve, Securities and Exchange Commission (Nigeria), Environment, IBC, Bank

We are also continuing to monitor economic conditions impacting our loan portfolio and have factored these forecasts into our allowance for credit loss calculation.

Key Points: 
  • We are also continuing to monitor economic conditions impacting our loan portfolio and have factored these forecasts into our allowance for credit loss calculation.
  • “Our net interest margin continues to be positively impacted by the current interest rate environment in light of the Federal Reserve Board’s actions to increase interest rates.
  • The cornerstone of our day-to-day decisions continues to be our proven legacy commitment to expense control and non-interest income growth to protect our earnings.
  • IBC is a multi-bank financial holding company headquartered in Laredo, Texas, with 168 facilities and 258 ATMs serving 75 communities in Texas and Oklahoma.

Publix Reports Third Quarter 2023 Results and Stock Price

Retrieved on: 
Wednesday, November 1, 2023
Family, LGBTQ+, Technology, Consumer, Other Retail, Teens, Parenting, Children, Supermarket, Office Products, Food, Beverage, Retail, Online Retail, Food Tech, Luxury, Other Consumer, Discount, Variety, Home Goods, Department Stores, Women, Seniors, Men, Bank statement, Comparable, Sale, Publix, GAAP, Securities and Exchange Commission (Nigeria), Clothing, Cryptocurrency, Insurance

Net earnings for the three months ended Sept. 30, 2023 were $833 million, compared to $394 million in 2022, an increase of 111.4%.

Key Points: 
  • Net earnings for the three months ended Sept. 30, 2023 were $833 million, compared to $394 million in 2022, an increase of 111.4%.
  • Earnings per share for the three months ended Sept. 30, 2023 increased to $0.25 per share, up from $0.12 per share in 2022.
  • Publix’s sales for the nine months ended Sept. 30, 2023 were $42.4 billion, an 8.1% increase from $39.2 billion in 2022.
  • Effective Nov. 1, 2023, Publix’s stock price increased from $14.75 per share to $15.10 per share.

MetLife Announces Third Quarter 2023 Results

Retrieved on: 
Wednesday, November 1, 2023
Banking, Professional Services, Insurance, Finance, Form, News, GAAP, MetLife, Table, Supplement, Securities and Exchange Commission (Nigeria), Reinsurance

Supplemental slides for the third quarter of 2023, titled “3Q23 Supplemental Slides,” are available on the MetLife Investor Relations website at https://investor.metlife.com and in the Form 8-K furnished by MetLife to the U.S. Securities and Exchange Commission in connection with this earnings release.

Key Points: 
  • Supplemental slides for the third quarter of 2023, titled “3Q23 Supplemental Slides,” are available on the MetLife Investor Relations website at https://investor.metlife.com and in the Form 8-K furnished by MetLife to the U.S. Securities and Exchange Commission in connection with this earnings release.
  • MetLife reported third quarter 2023 premiums, fees and other revenues of $13.2 billion, down 32 percent compared to the third quarter of 2022.
  • In the third quarter of 2023, MetLife performed the company's annual global actuarial assumption review.
  • The actuarial assumption review and other insurance adjustments during the quarter positively impacted net income by $8 million and adjusted earnings by $14 million.